Dr Murray Johns, a world-renowned authority on sleep medicine developed a special interest in the state of drowsiness and its associated dangers for people whose very lives depend on them remaining awake at the appropriate time. ​

He developed the world’s first and only technology capable of detecting drowsiness and alertness in real-time, using the eponymically named 10-point Johns Drowsiness Scale (JDS). 


The first prototype of Optalert Drowsiness Detection Glasses is created, using patented infrared (IR) reflectance technology to measure eye and eyelid movements.


A new research and development (R&D) company, Sleep Diagnostics Pty Ltd (later to become Optalert Limited) is formed as the owner of the associated intellectual property (IP), and to facilitate its further development.
Optalert Limited raises private equity capital in several steps until 2008.


During its first few years, Optalert carries out commercial prototype testing in-house, as well as in collaboration with independent research organisations, to validate the unique Johns Drowsiness Scale (JDS) in controlled laboratory settings and driving simulator studies.
Optalert carries out extensive field testing of the commercial prototype with Australian transport and mining companies.


In 2008, Optalert products become commercially available.
Optalert proceeds to develop into a commercial enterprise, adding manufacturing and distribution to the R&D function of the company.


Optalert continually redefines and improves its software and hardware to exceed market demands, including launching a new military spec, ruggedized unit in 2012.


The Eagle Industrial becomes the first Optalert product to use existing hardware. Lower installation time and over-the-air software updates means less down-time and increased productivity for sites across the world. Optalert begins talks to license its patented IP and algorithm to other user platforms.


The Eagle Portable combines Bluetooth wireless glasses delivering a world-first, allowing mobile and transferrable all-hour drowsiness detection. This enables users to be measured in and out of the workplace.


Optalert’s technology is successfully tested on video cameras – even at low sampling rates which open up the market for integration and licensing opportunities for autonomous and driver-operated vehicles.


Optalert develops the Eagle Research product, specifically for large pharmaceutical companies conducting clinical trials to test the impact of new drugs on wakefulness and sleepiness.


Optalert develops the BlinQTM system, the next generation in measuring drowsiness or wakefulness for pharmaceutical drug trials. The BlinQTM system, incorporates infra-red reflectance blepharometry with patented mathematical algorithms and measurement against the validated JDS. The term blepharometry is introduced by Dr Murray Johns, to define the unique study of measuring eyelid movement, captured through Infra-red reflectance, electro-oculography or video.


Optalert develops MISRA compliant drowsiness detection and validation software to license to Automotive OEMS allowing them to embed the technology in Advanced Driver Assistance Systems in preparation for introduction of Global Safety Regulation (EU) 2019/2144. 


Optalert launches its GSR 2019/2144 compliance solution, working with automotive indyustry participants to target 5 star Euro NCAP 2023 ratings.